Group 1 - Huafeng Co., Ltd. announced a stock suspension due to a potential change in control after signing a share transfer intention agreement [1] - Keshida plans to reduce its shareholding by up to 424,000 shares, representing 0.07% of its total share capital [1] - Jinqilin intends to distribute a cash dividend of 0.10 yuan per share, totaling 19.61 million yuan [1] Group 2 - Rejingshi Biotech has repurchased 904,100 shares, accounting for 0.98% of its total share capital, with a total expenditure of 150 million yuan [2] - Yishitong has repurchased 1,236,500 shares, representing 0.619% of its total share capital, with a total expenditure of approximately 33.49 million yuan [2] Group 3 - Hanjia Design announced the release of a detention on its subsidiary's chairman, allowing him to resume duties [4] - Qingmu Technology plans to acquire 65.83% of Vitalis Pharma AS for 300 million Norwegian Krone (approximately 212 million yuan) [4] - Anda Intelligent's shareholder plans to reduce its stake by up to 2.74% [4] Group 4 - Wansheng Intelligent is a candidate for a project with a pre-bid amount of approximately 42.99 million yuan, representing 4.56% of its audited revenue for 2024 [4] - Yipin Hong received a drug registration certificate for a medication used to treat Alzheimer's symptoms [4] Group 5 - *ST Sansheng received a total of 254 million yuan from restructuring investors [4] - Haichuang Pharmaceutical received approval for clinical trials of HP518 tablets for advanced prostate cancer treatment [4] Group 6 - Ningbo Huaxiang's subsidiary plans to invest 5 million yuan in a venture capital fund focusing on intelligent industries [4] - Petty Co. plans to repurchase shares worth 50 to 70 million yuan [4] Group 7 - Tongji Technology's subsidiary won a construction project with a bid price of 866 million yuan [4] - Prolo Pharmaceutical received a drug registration certificate for a generic drug [4] Group 8 - Jingyan Technology plans to use up to 1.6 billion yuan of idle funds for financial management [4] - Furan De received government subsidies totaling 34.65 million yuan [4] Group 9 - David Medical's subsidiary's medical device registration has been accepted [4] - Jusaylong plans to increase its subsidiary's capital by 170 million yuan through debt-to-equity conversion [4] Group 10 - Heng Rui Pharmaceutical's application for a drug license has been accepted by the National Medical Products Administration [4] - Lege Co. plans to increase its stake in the company by 40 to 80 million yuan [4] Group 11 - New Beiyang's subsidiary won a project with the Bank of Communications [4] - Jiangxi Changyun plans to publicly transfer land use rights and buildings with a starting price of 7.79 million yuan [4] Group 12 - Shenqi Pharmaceutical's subsidiary has paid approximately 16.67 million yuan in tax and penalties [4] - Panjiang Co. plans to invest 1.334 billion yuan in a power plant project [4] Group 13 - Fashilong's vice president resigned for personal reasons [4] - Chunxue Food received government subsidies of 3.79 million yuan [4] Group 14 - China Galaxy completed the repayment of a short-term financing bond totaling 3.025 billion yuan [4] - Jiuzhou Pharmaceutical received approval for a chemical raw material drug [4] Group 15 - Longqi Technology's subsidiary plans to invest 30 million yuan in a venture capital fund [4]

Core Viewpoint - Prolo Pharmaceutical (000739) announced that its wholly-owned subsidiary, Zhejiang Prolo Jutai Pharmaceutical Co., Ltd., has received a drug registration certificate from the National Medical Products Administration for Cefdinir Dry Suspension (1.5g; 3.0g) [1] Group 1: Product Information - Cefdinir Dry Suspension is classified as a third-generation oral cephalosporin antibiotic [1] - It is indicated for the treatment of mild to moderate infections in pediatric patients caused by specified sensitive strains of microorganisms under certain conditions [1] Group 2: Indications - The product is effective against acute bacterial otitis media caused by Haemophilus influenzae (including beta-lactamase producing strains), Streptococcus pneumoniae (only penicillin-sensitive strains), and Moraxella catarrhalis (including beta-lactamase producing strains) [1] - It is also indicated for pharyngitis/tonsillitis caused by Streptococcus pyogenes [1] - Additionally, it treats uncomplicated skin and skin structure infections caused by Staphylococcus aureus (including beta-lactamase producing strains) and Streptococcus pyogenes [1]

Core Viewpoint - Prolo Pharmaceutical's subsidiary has received a drug registration certificate for a new antibiotic, indicating a significant development in its product pipeline [1] Group 1: Company Developments - Prolo Pharmaceutical's wholly-owned subsidiary, Zhejiang Prolo Jutai Pharmaceutical Co., Ltd., has been granted a drug registration certificate by the National Medical Products Administration for Cefdinir Dry Suspension (1.5g; 3.0g) [1] - The newly approved Cefdinir Dry Suspension is classified as a third-generation oral cephalosporin antibiotic, aimed at treating mild to moderate infections in pediatric patients caused by specific sensitive strains of microorganisms [1] Group 2: Product Details - Cefdinir Dry Suspension is indicated for the treatment of acute bacterial otitis media caused by Haemophilus influenzae (including beta-lactamase producing strains), Streptococcus pneumoniae (only penicillin-sensitive strains), and Moraxella catarrhalis (including beta-lactamase producing strains) [1] - It is also indicated for pharyngitis/tonsillitis caused by Streptococcus pyogenes and uncomplicated skin and skin structure infections caused by Staphylococcus aureus (including beta-lactamase producing strains) and Streptococcus pyogenes [1]

Core Viewpoint - Prolo Pharmaceutical (000739.SZ) announced that its wholly-owned subsidiary, Zhejiang Prolo Jutai Pharmaceutical Co., Ltd., received a drug registration certificate from the National Medical Products Administration for Cefdinir Dry Suspension (1.5g; 3.0g) [1] Group 1 - Cefdinir Dry Suspension is classified as a third-generation oral cephalosporin antibiotic [1] - The drug is indicated for the treatment of mild to moderate infections in pediatric patients caused by specified strains of sensitive microorganisms under certain conditions [1] Group 2 - The specific infections targeted include acute bacterial otitis media caused by Haemophilus influenzae (including beta-lactamase producing strains), Streptococcus pneumoniae (only penicillin-sensitive strains), and Moraxella catarrhalis (including beta-lactamase producing strains) [1] - Additionally, it is effective for pharyngitis/tonsillitis caused by Streptococcus pyogenes and uncomplicated skin and skin structure infections caused by Staphylococcus aureus (including beta-lactamase producing strains) and Streptococcus pyogenes [1]

Core Viewpoint - The company has received approval for its cephalosporin product, marking a significant milestone in its market strategy and potential for growth [1] Group 1: Product Approval - The company's wholly-owned subsidiary, Zhejiang Pro Pharmaceutical Co., Ltd., has been granted a drug registration certificate for its cephalosporin dry suspension (1.5g; 3.0g) by the National Medical Products Administration [1] - This product is the first generic drug in China to be approved and deemed to have passed the consistency evaluation of quality and efficacy for generic drugs [1] Group 2: Market Implications - The approval allows the product to qualify for participation in national medical insurance negotiations, which is expected to enhance its market sales and competitiveness [1] - The company may face uncertainties in production and sales due to potential changes in policies, regulations, and market conditions [1]

证券代码：000739 证券简称：普洛药业 公告编号：2025-71 普洛药业股份有限公司 关于获得药品注册证书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 近日，普洛药业股份有限公司（以下简称"公司"）全资子公司浙江普洛巨 泰药业有限公司收到国家药品监督管理局（以下简称"药监局"）签发的头孢地 尼干混悬剂（1.5g；3.0g）《药品注册证书》。现将有关情况公告如下： 一、药品注册批准情况 1、产品名称：头孢地尼干混悬剂 2、剂型：口服混悬剂 3、规格：1.5g（125mg/5ml）；3.0g（250mg/5ml） 4、注册分类：化学药品 3 类 5、上市许可持有人：浙江普洛巨泰药业有限公司 6、生产企业：浙江普洛巨泰药业有限公司 7、证书编号：2025S03414；2025S03415 8、药品批准文号：国药准字 H20255948；国药准字 H20255949 9、审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查， 本品符合药品注册的有关要求，批准注册，发给药品注册证书。 普洛药业股份有限公司董事会 二、药品其他相关情况 头孢地尼干混 ...

Core Viewpoint - Pro Pharmaceutical Co., Ltd. has received a drug registration certificate for Cefdinir Dry Suspension from the National Medical Products Administration, indicating a significant advancement in its product offerings in the pediatric antibiotic market [1] Group 1: Company Developments - Pro Pharmaceutical's wholly-owned subsidiary, Zhejiang Proluo Jutai Pharmaceutical Co., Ltd., is the entity that received the registration certificate [1] - The newly approved Cefdinir Dry Suspension is classified as a third-generation oral cephalosporin antibiotic [1] Group 2: Product Information - Cefdinir Dry Suspension is indicated for the treatment of mild to moderate infections caused by sensitive strains of specified microorganisms in pediatric patients [1]

11月19日，普洛药业(000739.SZ)发布公告称，公司拟使用自有资金及金融机构回购贷款通过深圳 证券交易所交易系统以集中竞价交易方式回购公司股份，回购股份价格不超过人民币23元/股，回购资 金总额为不低于1.8亿元（含）且不超过3.6亿元（含）。 预计可回购股份数量为783万股—1565万股，约占公司总股本的0.68%—1.35%。回购期限为自董事 会审议通过回购股份方案之日起12个月内。 若公司在股份回购完成后36个月内未能实施前述用途，未使用部分将依法履行相关程序后予以注 销。 ...

证券代码：000739 证券简称：普洛药业 公告编号：2025-70 普洛药业股份有限公司 关于 2025 年第二次回购股份报告书 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 重要内容提示： 1.普洛药业股份有限公司（以下简称"公司"）于 2025 年 11 月 18 日召开 第九届董事会第十七次会议，经全体董事审议，一致通过了《关于 2025 年第二 次回购公司股份方案的议案》。根据《公司章程》的相关规定，本次回购股份方 案属于董事会审批权限范围，无需提交股东大会审议。 2.公司拟使用自有资金及金融机构回购贷款以集中竞价交易方式回购公司 股份，本次回购资金总额为人民币 18,000 万元—36,000 万元，本次回购股份价 格不超过人民币 23 元/股，未超过公司董事会通过回购股份决议前三十个交易日 公司股票交易均价的 150%。具体回购数量以回购期限届满或者回购股份实施完 毕时实际回购的股份数量为准。回购期限为自董事会审议通过回购股份方案之日 起 12 个月内。 3.公司已在中国证券登记结算公司深圳分公司开立了回购股份专用证券账 户。 4.截至本公告披 ...

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 普洛药业股份有限公司（以下简称"公司"）于2025年11月18日召开了第九 届董事会第十七次会议，审议通过了《关于2025年第二次回购公司股份方案的议 案 》 ， 并 于 2025 年 11 月 20 日 在 《 证 券 时 报 》 及 巨 潮 资 讯 网 （http://www.cninfo.com.cn）披露了《关于2025年第二次回购公司股份方案的 公告》（公告编号：2025-67）。 根据《上市公司股份回购规则》、《深圳证券交易所上市公司自律监管指引 第9号——回购股份》等相关规定，现将公司董事会公告回购股份决议的前一个 交易日（即2025年11月19日）登记在册的前十名股东和前十名无限售条件股东名 称、持股数量及占总股本比例情况公告如下： | 序号 | 持股人名称 | 持股数量（股） | 占总股本比例（%） | | --- | --- | --- | --- | | 1 | 横店集团控股有限公司 | 330,941,729 | 28.57 | | 2 | 浙江横店进出口有限公司 | 156,552,90 ...